🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →
Browsing Tag

London Stock Exchange

330 posts
IQE plc manufactures advanced compound-semiconductor wafers used in artificial intelligence data centres, optical communications, defence, satellites, smartphones, automotive sensors and power electronics. Representative image.
Read More

IQE plc company profile: How AI data centres and MACOM reshaped Britain’s compound-semiconductor wafer maker

IQE has emerged from weak smartphone demand, debt pressure and strategic uncertainty with a stronger balance sheet and rapidly growing exposure to artificial intelligence infrastructure. A £45 million strategic investment from customer MACOM, new indium phosphide supply agreements and upgraded 2026 guidance have transformed the near-term outlook, but dilution, manufacturing execution and a sharply higher valuation remain significant risks.
Defence Holdings is building a UK software-led defence platform around sovereign AI, the Meridian accelerator and its first £226,000 Ministry of Defence contract. Representative image.
Read More

Defence Holdings (LSE: ALRT) company profile: How the former Guild Esports listing pivoted into UK defence software

Defence Holdings PLC has transformed from the listed company formerly known as Guild Esports into an early-stage defence software and investment platform. Its first £226,000 UK Ministry of Defence contract and partnerships with Oracle and Whitespace provide initial validation, but the short contract duration, operating losses and rapid expansion of its share count leave the wider investment case unproven.
Avacta Group is advancing its pre|CISION tumour-targeted cancer platform through AVA6000 and AVA6103 as investors assess clinical validation, partnering prospects and funding risk. Representative image.
Read More

Avacta Group (AIM: AVCT) company profile: Can pre|CISION make potent cancer drugs safer and more targeted?

Avacta Group plc is developing peptide drug conjugates intended to release potent anticancer payloads primarily within the tumour microenvironment. Early AVA6000 findings and the launch of the AVA6103 trial have strengthened the scientific case, but larger clinical studies, partnership funding and management of the remaining convertible bond will determine whether pre|CISION creates sustainable shareholder value.